Adaptive Biotechnologies Corporation (MUN:1HM)
14.75
0.00 (0.00%)
At close: Dec 22, 2025
Adaptive Biotechnologies Employees
Adaptive Biotechnologies had 619 employees as of December 31, 2024. The number of employees decreased by 90 or -12.69% compared to the previous year.
Employees
619
Change (1Y)
-90
Growth (1Y)
-12.69%
Revenue / Employee
€348,017
Profits / Employee
€109,618
Market Cap
2.07B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 619 | -90 | -12.69% |
| Dec 31, 2023 | 709 | -81 | -10.25% |
| Dec 31, 2022 | 790 | -68 | -7.93% |
| Dec 31, 2021 | 858 | 236 | 37.94% |
| Dec 31, 2020 | 622 | 169 | 37.31% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Siemens Aktiengesellschaft | 317,562 |
| Deutsche Telekom AG | 198,194 |
| Mercedes-Benz Group AG | 175,264 |
| Bayerische Motoren Werke Aktiengesellschaft | 159,104 |
| Allianz SE | 156,626 |
| SAP SE | 109,121 |
| Siemens Energy AG | 98,995 |
| Deutsche Bank Aktiengesellschaft | 89,753 |
Adaptive Biotechnologies News
- 15 days ago - Adaptive Biotechnologies: 2026 Is The Durability Test, Not The Hype Cycle - Seeking Alpha
- 18 days ago - Adaptive Biotechnologies (ADPT) Leads Life Sciences Sector with 183.57% YTD Gain - GuruFocus
- 19 days ago - Adaptive Biotechnologies is the top performing life sciences tools and services stock YTD - Seeking Alpha
- 22 days ago - First Week of February 2026 Options Trading For Adaptive Biotechnologies (ADPT) - Nasdaq
- 26 days ago - Adaptive Biotechnologies signs non-exclusive deals with Pfizer worth up to $890 million - Reuters
- 26 days ago - Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer - GlobeNewsWire
- 4 weeks ago - Insider Sell: Robert Hershberg Sells 22,968 Shares of Adaptive Biotechnologies Corp (ADPT) - GuruFocus
- 4 weeks ago - Adaptive Biotechnologies to Participate in Jefferies Fireside Chat Series on Minimal Residual Disease - GlobeNewsWire